T0	Citation 15895 15899	[20]
T1	Citation 16349 16353	[20]
T2	MultiCitation 16471 16475	[20]
T3	MultiCitation 16614 16618	[20]
T4	Citation 20285 20289	[20]
T5	Citation 20853 20857	[20]
T6	Citation 39327 39331	[20]
T7	Span 15756 15899	We next examined this signature across intrinsic breast cancer subtypes, using the UNC337 tumor database comprising 337 breast tumor cases [20]
R1	Context Target:T0 Context:T7	
T8	Span 16171 16354	In contrast, the Basal-like and Claudin-low carcinomas are mostly triple negative breast cancers (ER-PR-Her2-) associated with high resistance to chemotherapy and poor prognosis [20].
R2	Context Target:T1 Context:T8	
T9	Span 16355 16482	Claudin-low tumors have been recently discovered through large-scale microarray analysis of breast cancer specimens [20], [22].
R3	Context Target:T2 Context:T9	
T10	Span 16483 16624	The MDA-MB-231 cell line used in this study was originally described as Basal B and has been recently characterized as Claudin-low [20], [21]
R4	Context Target:T3 Context:T10	
T11	Span 20129 20288	Claudin-low carcinomas and representative cell lines are characterized by a down-regulation of epithelial junction proteins, such as cadherins and claudins [20
R5	Context Target:T4 Context:T11	
T12	Span 20679 20858	CD44+/CD24- is considered a cancer stem cell or tumor initiating cell signature, and high CD44/CD24 ratios are characteristic of aggressive Claudin-low tumors and cell lines [20].
R6	Context Target:T5 Context:T12	
T13	Span 39308 39332	the UNC337-patient [20],
R7	Context Target:T6 Context:T13	
